These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 20038816)

  • 1. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
    Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
    Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR; Almenara JA; Coe S; Grant S
    Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
    Meng XW; Lee SH; Dai H; Loegering D; Yu C; Flatten K; Schneider P; Dai NT; Kumar SK; Smith BD; Karp JE; Adjei AA; Kaufmann SH
    J Biol Chem; 2007 Oct; 282(41):29831-46. PubMed ID: 17698840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.
    Huang R; Chen XQ; Huang Y; Chen N; Zeng H
    Asian J Androl; 2010 Jul; 12(4):527-34. PubMed ID: 20473320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
    Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
    Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    Wei G; Wang M; Hyslop T; Wang Z; Carr BI
    Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
    Wei G; Wang M; Carr BI
    J Cell Physiol; 2010 Jul; 224(1):112-9. PubMed ID: 20301194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
    Yuan BZ; Chapman J; Ding M; Wang J; Jiang B; Rojanasakul Y; Reynolds SH
    BMC Cancer; 2013 Mar; 13():140. PubMed ID: 23517112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
    Hamed HA; Yamaguchi Y; Fisher PB; Grant S; Dent P
    J Cell Physiol; 2013 Oct; 228(10):1996-2005. PubMed ID: 23674352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
    Pignochino Y; Grignani G; Cavalloni G; Motta M; Tapparo M; Bruno S; Bottos A; Gammaitoni L; Migliardi G; Camussi G; Alberghini M; Torchio B; Ferrari S; Bussolino F; Fagioli F; Picci P; Aglietta M
    Mol Cancer; 2009 Dec; 8():118. PubMed ID: 20003259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.
    Brüning A; Burger P; Vogel M; Gingelmaier A; Friese K; Burges A
    Invest New Drugs; 2010 Oct; 28(5):535-42. PubMed ID: 19554262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.
    Ricci MS; Kim SH; Ogi K; Plastaras JP; Ling J; Wang W; Jin Z; Liu YY; Dicker DT; Chiao PJ; Flaherty KT; Smith CD; El-Deiry WS
    Cancer Cell; 2007 Jul; 12(1):66-80. PubMed ID: 17613437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
    Fecteau JF; Bharati IS; O'Hayre M; Handel TM; Kipps TJ; Messmer D
    Mol Med; 2012 Feb; 18(1):19-28. PubMed ID: 21979753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
    Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
    BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.
    Panka DJ; Wang W; Atkins MB; Mier JW
    Cancer Res; 2006 Feb; 66(3):1611-9. PubMed ID: 16452220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
    Rahmani M; Davis EM; Bauer C; Dent P; Grant S
    J Biol Chem; 2005 Oct; 280(42):35217-27. PubMed ID: 16109713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
    Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
    Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
    Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
    Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
    Llobet D; Eritja N; Yeramian A; Pallares J; Sorolla A; Domingo M; Santacana M; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
    Eur J Cancer; 2010 Mar; 46(4):836-50. PubMed ID: 20071162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.